Figures & data
Figure 1. PRISMA flow diagram.
Table 1. Main characteristic of seven trials included in this meta-analysis.
Figure 2. (A) Risk of bias graph: A review of each risk of bias item as a percentage among the trials; (B) A summary of the risk of bias assessment.
Figure 3. A summary of the effects of aclidinium on (A) COPD exacerbations (B) exacerbation-related hospitalizations and (C) all-cause mortality.
Figure 4. A summary of the effects of aclidinium on the (A) changes in total SGRQ scores and (B) number of patients who achieved ≥ 4 units of improvement in their total SGRQ scores.
Figure 5. A summary of the effects of aclidinium on the (A) change in the TDI focal score and the (B) patients who achieved ≥ 1 unit of improvement in their TDI focal score.
Figure 6. A summary of the effects of aclidinium on the (A) change in trough FEV1 (ml) and (B) change in the peak FEV1 (ml).
Figure 7. A summary of the effects of aclidinium on the (A) change in trough FVC (ml) and the (B) change in peak FVC (ml).
Figure 8. A summary of the effects of aclidinium on (A) non-fatal serious adverse events and (B) adverse cardiac events.
Figure 9. A funnel plot of COPD exacerbations based on a comparison the aclidinium and placebo groups.
